The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[2]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[3]  A. Haese*,et al.  External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. , 2015, The Journal of urology.

[4]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[5]  F. Montorsi,et al.  Early radiotherapy after radical prostatectomy improves cancer‐specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria , 2015, International journal of urology : official journal of the Japanese Urological Association.

[6]  M. Terris,et al.  The impact of pathologic staging on the long‐term oncologic outcomes of patients with clinically high‐risk prostate cancer , 2014, Cancer.

[7]  M. Terris,et al.  Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. , 2014, European urology.

[8]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[9]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[10]  N. Murray,et al.  Secondary Circulating Prostate Cells Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease , 2013, TheScientificWorldJournal.

[11]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[12]  M. Cooperberg,et al.  The CAPRA‐S score , 2011, Cancer.

[13]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[14]  Mei-Jie Zhang,et al.  Marginal Models for Clustered Time‐to‐Event Data with Competing Risks Using Pseudovalues , 2011, Biometrics.

[15]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[16]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Chin,et al.  UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL , 2008 .

[18]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[19]  E. Bergstralh,et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.

[20]  John P Klein,et al.  Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence Function , 2005, Biometrics.